

Michel Vallee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4720616/publications.pdf>

Version: 2024-02-01

42
papers

3,358
citations

430754

18
h-index

276775

41
g-index

42
all docs

42
docs citations

42
times ranked

4410
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
2	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
3	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
4	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
5	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
6	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
7	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
8	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 "blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	0.8	170
9	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
10	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
11	Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2136-2142.	2.2	124
12	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
13	Characterization of UDP-glucuronosyltransferases active on steroid hormones. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 413-423.	1.2	101
14	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
15	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 "blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	0.8	60
16	Outcomes of Infection-Related Hospitalization according to Dialysis Modality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 817-824.	2.2	45
17	Association of Dialysis Modality with Risk for Infection-Related Hospitalization. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1598-1605.	2.2	42
18	Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. International Journal of Infectious Diseases, 2012, 16, e41-e43.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Association of Neutrophil-to-Lymphocyte Ratio With Inflammation and Erythropoietin Resistance in Chronic Dialysis Patients. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811773556.	0.6	15
20	Isolation and characterization of the monkey UDP-glucuronosyltransferase cDNA clone monUGT1A01 active on bilirubin and estrogens. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 77, 239-249.	1.2	14
21	Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw268.	0.4	12
22	Trends in infection-related hospital admissions and impact of length of time on dialysis among patients on long-term dialysis: a retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E109-E114.	1.1	11
23	The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications. <i>Canadian Journal of Cardiology</i> , 2018, 34, 665-669.	0.8	11
24	Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. <i>BMC Medical Research Methodology</i> , 2013, 13, 51.	1.4	9
25	Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations. <i>International Urology and Nephrology</i> , 2009, 41, 983-988.	0.6	8
26	Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients. <i>BMC Nephrology</i> , 2014, 15, 27.	0.8	8
27	Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. <i>Experimental and Clinical Transplantation</i> , 2014, 12, 323-7.	0.2	8
28	Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents. <i>Biomarker Insights</i> , 2016, 11, BMI.S39199.	1.0	6
29	Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. <i>International Urology and Nephrology</i> , 2017, 49, 325-328.	0.6	6
30	Regulation of 21-Hydroxylase activity by steroids. <i>Endocrine Research</i> , 1995, 21, 329-341.	0.6	5
31	Hemodialysis effects on phenytoin pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 499-500.	0.8	5
32	Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 301-311.	0.8	5
33	High mortality after pelvis and lower limb fractures in ESRD. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 466-466.	1.4	4
34	The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D. <i>International Urology and Nephrology</i> , 2015, 47, 1165-1171.	0.6	3
35	Pharmacokinetic and Dynamic of Furosemide in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 107-108.	1.1	3
36	Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation. <i>Journal of Transplantation</i> , 2017, 2017, 1-6.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience. Canadian Journal of Diabetes, 2018, 42, 205-208.	0.4	3
38	The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 989-990.	0.3	3
39	Regulation of guinea pig adrenal P450c21 messenger RNA, protein and activity by RU486. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 31-38.	1.2	2
40	Difficulty of patient selection in a combined heart-kidney transplant: a case report. Experimental and Clinical Transplantation, 2014, 12, 273-6.	0.2	2
41	Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 895-896.	0.3	1
42	Presumed paradoxical embolus in a patient with diabetic ketoacidosis. International Journal of General Medicine, 2015, 8, 297.	0.8	0